News & Events

  -“IMFINZI is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer”, presented at WCLC plenary… CASPIAN trial

Zhao W, Liu Y, Jenkins BD, Cheng R, Harris BN, Zhang W, Xie J, Murrow JR, Hodgson J, Egan M, Bankey A, Nikolinakos PG, Ali… Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.

Weiss JM1, Csoszi T2, Maglakelidze M3, Hoyer RJ4, Beck JT5, Gomez MD6, Lowczak A7, Aljumaily R8, Lima CMR9, Boccia RV10, Hanna W11, Nikolinakos P12, Chiu… Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.

Yardley DA1, Hart L2, Favret A3, Blau S4, Diab S5, Richards D6, Sparano J7, Beck JT8, Richards P9, Ward P10, Ramaswamy B11, Tsai M12, Blackwell… Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer:… The SPRUCE Trial.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2683625